Three leaders in radiation oncology have been named recipients of the American Society for Radiation Oncology (ASTRO) Gold Medal. Benedick A. Fraass, PhD, FASTRO; Christopher G. Willett, MD, FASTRO; and Anthony L. Zietman, MD, FASTRO; will be recognized at an awards ceremony during ASTRO’s 58th...
In the ongoing debate over how to control rising cancer care costs, it is vital to identify usage patterns of expensive new technologies. A recent study examined the relationship between Medicare reimbursement and the increasing use of intensity-modulated radiation therapy (IMRT).1 The ASCO Post...
Men with newly diagnosed localized prostate cancer face a decision between prostatectomy and radiotherapy, treatments deemed similarly effective but with well-established trade-offs in terms of treatment-related morbidity. Numerous clinical trials and other prospective studies, from both academic...
Active surveillance is well established as an appropriate management option for men with low-risk prostate cancer and particularly for those over 65 years of age. Its legitimacy is now enshrined within National Comprehensive Cancer Network guidelines, in the American Society for Radiation Oncology...